Compare SGHT & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SGHT | NHS |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.4M | 203.4M |
| IPO Year | 2021 | N/A |
| Metric | SGHT | NHS |
|---|---|---|
| Price | $3.83 | $6.52 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.08 | N/A |
| AVG Volume (30 Days) | 230.7K | ★ 334.7K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.44% |
| EPS Growth | ★ 28.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,363,000.00 | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $10.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.51 | $6.27 |
| 52 Week High | $9.24 | $7.75 |
| Indicator | SGHT | NHS |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 37.71 |
| Support Level | $3.30 | $6.27 |
| Resistance Level | $4.29 | $6.65 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 65.26 | 69.74 |
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.